Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2

Conditions

Constipation 3Neoplasms 2Intestinal Diseases 2Peritoneal Neoplasms 1Opioid-Induced Constipation 1Ileus 1Cancer Pain 1

Interventions

alvimopan 2Oxaliplatin 2Capecitabine 2pembrolizumab 1alectinib 1Ocoxin 1Folfox protocol 1Cyclophosphamide 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Diseases × alvimopan × Clear all
NCT00101998 2017-08-30

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
233 enrolled
Other

Cancer Pain, Constipation, Intestinal Diseases

NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
67 enrolled
Other

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡